Circular RNAs at the intersection of cancer and heart disease: potential therapeutic targets in cardio-oncology

Considerable progress has been made for managing cancer, however, with these advancements, comes the discovery of previously unknown adverse events. In particular, the prolonged lifespan of patients has uncovered severe cardiotoxic side effects of widely used anticancer therapies, which restrict their administration and thus compromise the success of the seemingly most suitable treatments in large cancer patient cohorts. Vice versa, cardiovascular diseases can also promote both the onset and progression of different cancers, highlighting that both conditions are deeply interlinked. Recognizing these close interactions, the novel interdisciplinary field of cardio-oncology has emerged to closely study these uniquely correlating diseases. In this regard, non-coding RNAs are gaining increasing attention since they constitute crucial regulators in many physiological but also pathological signaling pathways, including those of cancer and cardiac dysfunction. In this review, we focus on the new subtype of non-coding RNA, circular RNAs, in their distinct exchange within cardio-oncology and discuss their suitability as potent targets for the simultaneous treatment of cardiac dysfunction and cancer.